Ilaria Cossu | Immunology Cellular Interactions | Research Excellence Award

Published on by Cell Biologist

Ms. Ilaria Cossu | Immunology Cellular Interactions | Research Excellence Award

University of Sassari | Italy

Ilaria Cossu is a motivated PhD candidate in Life Sciences and Biotechnologies with a specialization in Microbiology and Immunology. Their work focuses on understanding the role of human endogenous retroviruses (HERVs) in cancer, integrating molecular biology, immunology, and virology approaches to explore how retroviral elements may influence tumorigenesis. Their doctoral project involves conducting indirect ELISA assays, maintaining and analyzing cell cultures, processing blood samples, performing RNA extraction and reverse transcription, and carrying out quantitative PCR for gene expression profiling. The researcher is actively engaged in experimental design, data analysis, scientific writing, and collaborative research activities at both national and international levels.

Prior academic training includes Master’s and Bachelor’s degrees in Biology, each completed with top distinction, and research internships in microbiology, virology, and biochemistry laboratories. These experiences provided hands-on expertise in electrophoretic methods such as cellulose acetate electrophoresis, C-PAGE, fluorescent 2-aminoacridone probe (FACE) analysis, and SDS-PAGE, contributing to a solid foundation in protein and nucleic acid characterization. Their current research aims to advance understanding of retroviral contributions to cancer biology and supports the development of innovative molecular approaches for disease investigation and potential therapeutic insights.

Profile: Scopus

Featured Publications:

Cossu, I., Ruberto, S., Filippi, E., Simula, E. R., Noli, M., Mottula, A., & others. (2025). HERV-K envelope induces a humoral response in Non-Hodgkin lymphoma patients. Current Microbiology, 82(12), 574.

Jasemi, S., Molicotti, P., Fais, M., Cossu, I., Simula, E. R., Sechi, L. A., & others. (2025). Biological mechanisms of enterotoxigenic Bacteroides fragilis toxin: Linking inflammation, colorectal cancer, and clinical implications. Toxins, 17(6), 305.

Simula, E. R., Jasemi, S., Cossu, D., Fais, M., Cossu, I., Chessa, V., & others. (2025). Human endogenous retroviruses as novel therapeutic targets in neurodegenerative disorders. Vaccines, 13(4), 415. h

Ruberto, S., Santovito, A., Caviglia, G. P., Noli, M., Cossu, D., Ribaldone, D. G., & others. (2025). Mycobacterium avium subsp. paratuberculosis and human endogenous retrovirus in Italian patients with inflammatory bowel disease and irritable bowel syndrome. Immunology.

Kimberly Gilmour | Immunology Cellular Interactions | Women Researcher Award

Published on by Cell Biologist

Dr. Kimberly Gilmour | Immunology Cellular Interactions | Women Researcher Award

Great Ormond Street Hospital | United Kingdom

Kimberly Coughlan Gilmour is a leading expert in immunology, molecular diagnostics, and cell-based therapeutic development. Her early academic work contributed foundational insights into cytokine signaling, particularly the regulation of the Interferon Regulatory Factor-1 (IRF-1) gene and the signal transduction pathways activated by prolactin and interleukin-2. During her postdoctoral research, she investigated mechanisms governing thymocyte proliferation and differentiation using retroviral manipulation of murine thymic organ cultures, advancing understanding of T-cell development.

Gilmour has played a pivotal role in the evolution of clinical immunology diagnostics, leading the development of national services for the molecular diagnosis of primary immunodeficiency disorders. She has been instrumental in translating complex research methodologies—including gene expression analysis, retroviral and lentiviral transduction, and thymus tissue culture—into routine clinical tools that directly inform patient management. Her work supports post-treatment monitoring for haematopoietic stem cell transplantation, gene therapy, and targeted antibody-based interventions.

As a leader in cell therapy, she has overseen the implementation of advanced cellular manufacturing processes and supervised the clinical authorization of personalized therapeutic products. Her career integrates immunogenetics, translational science, and cellular therapy innovation, significantly shaping clinical practice for paediatric patients with rare and complex immune disorders.

Profiles: Scopus | Orcid

Featured Publications:

  • Maimaris, J., Roa-Bautista, A., Sohail, M., et al. (2025). Griscelli Syndrome Type 2: Comprehensive analysis of 149 new and previously described patients with RAB27A deficiency. Journal of Clinical Immunology, 45(50).

  • Author(s) Unknown. (2025). Safety and diagnostic utility of brain biopsy and metagenomics in decision-making for patients with inborn errors of immunity (IEI) and unexplained neurological manifestations. Journal of Clinical Immunology, 45, 86.

  • Booth, C., Masiuk, K., Vazouras, K., Fernandes, A., Xu-Bayford, J., Campo Fernandez, B., Roy, S., Curio-Penny, B., Arnold, J., Terrazas, D., Reid, J., Gilmour, K. C., Adams, S., Mediavilla, E. A., Mhaldien, L., O’Toole, G., Ahmed, R., Garabedian, E., Malech, H., De Ravin, S. S., Moore, T. B., De Oliveira, S., Pellin, D., Lin, T.-Y., Dang, T. T., Cornetta, K., Hershfield, M. S., Hara, H., Thrasher, A. J., Gaspar, H. B., & Kohn, D. B. (2025). Long-term safety and efficacy of gene therapy for adenosine deaminase deficiency. New England Journal of Medicine, 393(15), 1486–1497.

  • Guardo, D., Mishra, A. K., Rashed, H., Gilmour, K. C., Adams, S., Pinner, D., Sauer, M., Vora, A., Veys, P., Pavasovic, V., Rao, K., & Qasim, W. (2025). Long-term outcomes of genome-edited “universal” CAR19 T cells for relapsed/refractory B-ALL at a single pediatric center. Blood Advances, 9(18), 4750–4754.

 

Wan Wan Lin | Inflammation | Best Researcher Award

Published on by Cell Biologist

Prof. Wan Wan Lin | Inflammation | Best Researcher Award

Department of Pharmacology, College of Medicine, NTU | Taiwan

Dr. Wan-Wan Lin is a leading researcher in the fields of pharmacology and immunology, with a strong focus on cellular signaling and innate immune mechanisms. Her work has significantly advanced understanding of signal transduction pathways and their regulation of inflammation and cell death. She has made notable contributions to the study of pattern recognition receptors, inflammasomes, and cytokine-mediated immune responses, particularly in the context of oxidative stress and mitochondrial function. Dr. Lin’s research explores how mitochondrial dynamics and redox balance influence inflammatory signaling and programmed cell death, providing key insights into the molecular basis of immune regulation and inflammatory diseases. Her studies have also shed light on the crosstalk between cellular stress responses and immune activation, offering potential therapeutic targets for controlling excessive inflammation and tissue damage. Recognized for her excellence in research, Dr. Lin has received multiple national awards and continues to contribute to the advancement of pharmacological sciences through her editorial and academic roles. Her integrative approach bridges pharmacology, immunology, and cell biology, driving innovations in the understanding of molecular mechanisms underlying inflammation and innate immunity.

Profile: Orcid

Featured Publications:

Lin, W.-W., Lee, C.-Y., Tsai, M.-C., & Tsaur, M.-L. (1985). Pharmacological study on angusticeps-type toxins from mamba snake venoms. Journal of Pharmacology and Experimental Therapeutics, 233, 491–498.

Lin, W.-W., Chang, P.-L., Lee, C.-Y., & Joubert, F. J. (1987). Pharmacological study on phospholipases A₂ isolated from Naja mossambica mossambica venom. Proceedings of the National Science Council, Republic of China B, 11, 155–163.

Lin, W.-W., Lee, C.-Y., & Burnett, J. W. (1988). Effect of sea nettle (Chrysaora quinquecirrha) venom on isolated rat aorta. Toxicon, 26, 1209–1212.

Chiou, S.-H., Lin, W.-W., & Chang, W.-P. (1989). Sequence characterization of venom toxins from Thailand cobra. International Journal of Peptide and Protein Research, 34, 148–152.

Lee, C.-Y., Lin, W.-W., Chen, Y.-M., & Lee, S.-Y. (1989). Is direct cardiotoxicity the primary cause of death following intravenous injection of the basic phospholipase A₂ from Naja nigricollis venom? Acta Physiologica et Pharmacologica Latinoamericana, 39, 383–391.

Lee, C.-Y., & Lin, W.-W. (1989). Two subtypes of acetylcholinesterase isoenzymes distinguishable by Angusticeps-type toxin F7. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology and Toxicology, 92, 279–281.

Lin, W.-W., Lee, C.-Y., & Chuang, D.-M. (1989). Cross-desensitization of endothelin- and sarafotoxin-induced phosphoinositide turnover in neurons. European Journal of Pharmacology, 166, 581–582.

Lin, W.-W., Chen, Y.-M., Lee, S.-Y., Nishio, H., Kimura, T., Sakakibara, S., & Lee, C.-Y. (1990). Cardiovascular effects of two disulfide analogues of sarafotoxin S6b. Toxicon, 28, 911–923.

Lin, W.-W., Lee, C.-Y., Yasumoto, T., & Chuang, D.-M. (1990). Maitotoxin induces phosphoinositide turnover and modulates glutamatergic and muscarinic cholinergic receptor function in cultured cerebellar neurons. Journal of Neurochemistry, 55, 1563–1568.

Lin, W.-W., & Lee, C.-Y. (1990). Biphasic effects of endothelin in the guinea-pig ileum. European Journal of Pharmacology, 176, 57–62.

Zhihua Wu | Allergen | Best Researcher Award

Published on by Cell Biologist

Mr. Zhihua Wu | Allergen | Best Researcher Award

Nanchnag University | China

Dr. Zhihua Wu is a leading researcher in the field of food science and nanobiotechnology, with a focus on food protein processing, allergen characterization, and functional food development. His work explores the structural and immunological properties of food allergens, particularly those derived from peanuts, soybeans, and almonds, aiming to elucidate mechanisms underlying allergenicity and cross-reactivity. He employs advanced analytical tools such as mass spectrometry, metabolomics, and molecular modeling to investigate how food processing, polyphenol interactions, and roasting alter protein structures and immune responses. Dr. Wu’s recent studies have provided key insights into epitope localization and allergen modification for risk reduction in plant-based foods. His ongoing research projects, funded by major Chinese national programs, include developing safety evaluation and risk mitigation techniques for plant-derived food resources and mapping IgE-binding epitopes of 2S albumins. He also contributes to the understanding of food flavor chemistry, especially changes in tea aroma compounds during processing and storage. Recognized through multiple provincial and national science awards, Dr. Wu’s research advances the interface of food safety, protein chemistry, and functional nutrition, offering innovative strategies for producing hypoallergenic and health-promoting food products.

Profile: Scopus

Featured Publications:

Wu, Z., Gao, K., Geng, Q., Hu, C., Zhang, W., Li, X., Tong, P., Yang, A., & Chen, H. (2025). Impact of the polyphenol structure on the allergenic potential of the peanut allergen Ara h 2. Journal of Agricultural and Food Chemistry, 73(28), 17967–17979.

Hu, C., Luo, Q., Zhou, L., Zhu, W., Gao, K., Geng, Q., Li, X., Yang, A., Tong, P., Wu, Z., & Chen, H. (2025). Purification of Pru du 6 from almond and its cross-reactivity with Gly m 6 from soybean. International Journal of Molecular Sciences, 26(11), 5425.

Zhang, Y., Zhang, J., Li, X., Yang, A., Tong, P., Wu, Z., & Chen, H. (2025). Untargeted metabolomics reveals changes in serum metabolism in peanut-allergic mice treated by raw and roasted peanuts. Food Science and Human Wellness.

Zhou, W., Geng, Q., Zhang, Y., Zhou, X., Wu, Z., Chen, H., & El-Sohaimy, S. (2024). The flavonoid-allergen interaction and its influence on allergenicity. Food Bioscience, 61, 104939. h

Zhang, Y., Geng, Q., Song, M., Li, X., Yang, A., Tong, P., Wu, Z., & Chen, H. (2024). The structure and potential allergenicity of peanut allergen monomers after roasting. Food & Function, 15, 2577–2586.

Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Assist. Prof. Dr. Alejandro Rojas | Austral University of Chile | Germany

Dr. Alejandro Alfredo Rojas Fernández is a distinguished Chilean molecular biotechnologist and neuroscientist, currently serving as CEO of Berking Theranostics UG in Hamburg, Germany, and Assistant Professor at the Universidad Austral de Chile. With over two decades of research spanning neurodegeneration, immunology, and viral pathogenesis, Dr. Rojas-Fernández has emerged as a leading expert in molecular diagnostics and theranostics. His innovative work has significantly impacted global health, notably through his contributions to SARS-CoV-2 research and senolytic therapies. A dual academic and entrepreneur, he bridges fundamental science and clinical application, actively publishing in top-tier journals such as Nature Aging, Molecular Psychiatry, and Journal of Cell Biology. Fluent in interdisciplinary collaboration, his efforts have been internationally recognized with multiple honors. With a passion for translational science, Dr. Rojas-Fernández continues to inspire the next generation of biomedical innovators through mentorship and leadership in biotechnology and neuroscience.

Publication Profile:

Orcid

Education:

Dr. Alejandro Rojas-Fernández earned his PhD in Biology from the University of Konstanz, Germany (2006–2010), where his research focused on the regulation of Hdm2/HdmX-mediated ubiquitination and neddylation—mechanisms central to protein stability and cancer biology. Prior to his doctorate, he completed his engineering degree in Molecular Biotechnology (2004–2005) and his B.Sc. in Molecular Biotechnology Engineering (2000–2004) at the Faculty of Sciences, University of Chile—one of Latin America’s leading research institutions. His multidisciplinary education integrates molecular biology, neurobiology, immunology, and translational medicine, equipping him with the foundational and advanced tools to tackle complex biomedical challenges. Dr. Rojas-Fernández’s academic training has been marked by academic excellence and international mobility, enabling him to collaborate and lead research projects across Europe and Latin America.

Experience:

Dr. Rojas-Fernández brings over 20 years of experience in translational biomedical research, academia, and biotech innovation. As CEO of Berking Theranostics UG, he spearheads the development of personalized diagnostic platforms and therapeutics, with a focus on neurodegenerative and inflammatory diseases. In his role as Assistant Professor at Universidad Austral de Chile (20% appointment), he leads the Medical Biotechnology Laboratory within the Centre for Interdisciplinary Studies on the Nervous System (CISNe), contributing to scientific training and cutting-edge research. He previously trained and collaborated at institutions such as the University of Dundee, University of Queensland, and University of Constance, advancing molecular mechanisms of SUMOylation, proteostasis, inflammasome biology, and viral-host interactions. His interdisciplinary expertise allows him to translate complex cellular insights into tangible clinical applications, and his leadership has resulted in high-impact publications, product pipelines, and strategic biotech partnerships in Europe and Latin America.

Awards and Honors:

Dr. Rojas-Fernández has received multiple prestigious honors recognizing his innovative biomedical research. In February 2025, he was named “Innovator of the Month” by Hamburg Invest for groundbreaking biotech contributions in Germany. He was awarded the Medal of the City of Valdivia for his vital role in controlling the SARS-CoV-2 pandemic, one of the highest local honors in Chile. Additionally, he received the 2nd of October Medal for Science and Innovation, recognizing his scientific leadership in Chile’s Los Ríos region. These accolades underscore his impact on global public health, neurodegenerative research, and biotechnology entrepreneurship. His consistent recognition reflects a career dedicated to translational excellence, fostering international collaboration, and advancing science for the benefit of society. His scientific achievements continue to inspire innovation and interdisciplinary approaches within the global scientific community.

Research Focus:

Dr. Alejandro Rojas-Fernández’s research centers on cellular stress responses, ubiquitin/SUMO signaling, neurodegeneration, and host-pathogen interactions. A core focus is the molecular crosstalk between autophagy, protein quality control, and inflammasome activation in brain and immune cells. He has made significant advances in understanding the effects of SARS-CoV-2 on microglia, mechanisms of senescence in aging brains, and nanobody-based viral neutralization. His studies also explore the intersection of endoplasmic reticulum stress and neurodegenerative pathways, using high-content screening and proteomics to uncover therapeutic targets. He actively translates molecular insights into diagnostics and theranostic tools, positioning him at the forefront of personalized medicine. As CEO of a biotech startup, he is developing platforms that integrate biomarker discovery with AI for neuroinflammation profiling. His research bridges fundamental biology and clinical applications, promoting innovative therapies for Alzheimer’s, Parkinson’s, cancer, and viral infections.

Publications Top Notes: 

  1. Negative Modulation of Macroautophagy by Stabilized HERPUD1… – Front Cell Dev Biol, 2022

  2. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia… – Mol Psychiatry, 2022

  3. The p97/VCP segregase is essential for arsenic-induced degradation of PML… – J Cell Biol, 2023

  4. Lack of Parkinsonian Pathology after Proteasome Inhibitor Injection… – Front Aging Neurosci, 2021

  5. NSPA modulates postsynaptic NMDAR stability… – BMC Biol, 2020

  6. Role of PSMD14 in Golgi-to-ER transport and APP processing – Cells, 2020

  7. WDR90 in NLRC4 inflammasome and Salmonella resistance – Dev Comp Immunol, 2019

  8. Proteomic identification of APC interaction partners – Mol Cancer Res, 2019

  9. DHX15 regulates CMTR1-dependent gene expression – Life Sci Alliance, 2018

  10.  Membrane ruffling by polarized stim1 and orai1 – Sci Reports, 2017

Conclusion:

Dr. Alejandro Alfredo Rojas Fernández stands out as a pioneering researcher who consistently delivers scientifically rigorous, socially impactful, and clinically relevant work. His career spans critical sectors—basic research, applied biotechnology, and public health—making him a model example of the translational scientist. With accolades from both European and Latin American institutions and a track record of high-impact publications, Dr. Rojas exemplifies what it means to be a globally relevant and community-driven scientist. His work during the COVID-19 pandemic, innovations in molecular neuroscience, and leadership in therapeutic biotechnology underscore his immense value to the global research community. In conclusion, he is not only a suitable but a highly deserving candidate for the Best Researcher Award.

Alaka Sahoo | Immunology Cellular Interactions | Young Researcher Award

Published on by Cell Biologist

Mrs. Alaka Sahoo | Immunology Cellular Interactions | Young Researcher Award

Mrs. Alaka Sahoo, Siksha’O’ Anusandhan University, India

Dr. Alaka Sahoo is a dedicated young researcher in the field of Biotechnology with a focus on translational and clinical research. She holds a Ph.D. in Biotechnology from Siksha ‘O’ Anusandhan University, Odisha, with a CGPA of 8.90. With over 17 publications, including 11 research articles and 3 high-impact reviews, Dr. Sahoo has significantly contributed to oral disease therapeutics and antimicrobial studies. She demonstrates expertise in multi-omics analysis, drug discovery, and natural product-based therapy. A recipient of prestigious awards such as the Lalchand Women Entrepreneurs Award (2024), she is also a life member of reputed organizations like the British Society for Antimicrobial Chemotherapy. Her innovative approach to disease management using phytochemicals and peptides sets her apart as a rising talent in biomedical research.

Publication Profile: 

Google Scholar

Scopus

Orcid

✅ Strengths for the Award:

  1. Strong Publication Record:

    • 17 publications including 11 original research, 3 reviews, and 2 book chapters, showcasing depth and breadth.

    • 7 papers as first or corresponding author—indicating independent research capability.

    • Research in high-impact journals like Frontiers in Microbiology, Journal of Ethnopharmacology, Nanomaterials, and Chemistry & Biodiversity.

  2. Innovative & Multidisciplinary Research:

    • Integrates multi-omics, computational modeling, clinical dermatology, and natural products.

    • Focus on oral inflammatory diseases, antimicrobial peptides, and drug delivery systems.

  3. Academic Excellence & Research Training:

    • Ph.D. with 8.90 CGPA, and M.Sc. with 87.07% marks.

    • Expertise in BSL-2+ lab work, PCR, ELISA, microbial culture, and molecular docking.

  4. Awards & Recognition:

    • Lalchand Women Entrepreneurs Award (2024).

    • MSME-Idea Hackathon Innovation Award, Govt. of India.

  5. Global and National Engagement:

    • Life member of the British Society for Antimicrobial Chemotherapy (UK).

    • Demonstrates leadership in science entrepreneurship and women in research.

🛠️ Areas for Improvement:

  1. Expanded International Collaboration:

    • Building long-term research partnerships with international labs could increase global visibility.

  2. Patent/Technology Transfer Efforts:

    • While publications are strong, translating research into patents or commercial products will further strengthen applied impact.

  3. Focused Project Leadership:

    • Leading large interdisciplinary projects or acquiring independent grants will showcase funding leadership.

🎓 Education:

Dr. Alaka Sahoo has pursued a progressive academic path in Biotechnology. She earned her Ph.D. in Biotechnology from the School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan Deemed University, Odisha, completing her research with a notable 8.90 CGPA. Her thesis focused on “Therapeutic Opportunities for Oral Lichen Planus: An Integrated Multi-Omics Approach to Drug Discovery” under the guidance of Prof. (Dr.) Maitreyee Panda. Prior to this, she completed her M.Sc. in Biotechnology (87.07%) from the College of Basic Science and Humanities, OUAT, Bhubaneswar in 2018 and a B.Sc. in Biotechnology with distinction (75%) from Ramadevi Women’s College, Utkal University in 2016. Her academic journey showcases a strong foundation in both theoretical and applied aspects of biosciences.

💼 Experience:

Dr. Alaka Sahoo brings rich hands-on research experience in clinical and experimental biotechnology. She is skilled in BSL-2+ lab practices, molecular techniques like PCR, gel electrophoresis, microbial culture, ELISA-based diagnostics, and bioinformatics. Her doctoral work integrated multi-omics and computational biology to study inflammatory oral diseases, and her postdoctoral research spans drug delivery and antimicrobial drug discovery. As first or corresponding author in 7 out of 17 publications, she has led collaborative studies with both national and international partners. Dr. Sahoo’s cross-disciplinary knowledge in microbiology, pharmacology, and nanomedicine enhances her problem-solving abilities, making her a versatile researcher. Her ability to bridge clinical dermatology with biotechnology research positions her as an impactful contributor in both healthcare and academic environments.

🏆 Awards & Honors:

Dr. Alaka Sahoo has received notable accolades for her innovation and leadership in science. In 2024, she was awarded the Lalchand Women Entrepreneurs Award by the Odisha Corporate Foundation, recognizing her outstanding contributions in biotech innovation. She also earned the MSME-Idea Hackathon 3.0 (Women) Innovation Award by the Government of India, honoring her practical scientific advancements with societal impact. These awards reflect her dedication to translational research and her vision to develop cost-effective, natural therapies. Dr. Sahoo is also a life member of two esteemed organizations: the British Society for Antimicrobial Chemotherapy (UK) and Bioclues Innovation, Research and Development (India). Her achievements signify her rising prominence in the field and her commitment to addressing public health challenges through integrative research.

🔬 Research Focus:

Dr. Alaka Sahoo’s research focuses on oral inflammatory diseases, natural product therapeutics, and insect-derived peptides as alternatives to conventional antimicrobials. Her Ph.D. thesis explored multi-omics approaches for drug discovery in Oral Lichen Planus, integrating in vitro, in silico, and clinical data. Her work spans immunomodulation, anti-inflammatory drug screening, and nanodrug delivery systems, with cross-functional expertise in dermatology, pharmacology, and microbiology. She combines computational modeling, molecular docking, and wet-lab validation to develop target-specific therapies. Her studies on biofilm inhibition, antifungal peptides, and phytosteroids hold promise for tackling antimicrobial resistance. Through collaborations across academia and healthcare, she aims to translate her lab findings into clinically viable solutions. Her contributions to systematic reviews and molecular simulations further demonstrate her analytical rigor and commitment to evidence-based research.

📚 Publications Top Notes:

  1. 📘 Experimental and clinical trial investigations of phytoextracts in Oral Lichen Planus: A systematic review – J Ethnopharmacol (2022)

  2. 🐞 Insect-derived antimicrobial peptides as novel anti-biofilm agents: A systematic review – Front. Microbiol. (2021)

  3. 💊 Ultraflexible liposome nanocargo for dermal drug delivery – Nanomaterials (2021)

  4. 🌿 Phytochemicals for Oral Lichen Planus: A multi-omics and experimental study – Chem Biodivers (2025)

  5. ⚗️ Carbohydrate-derived N-benzyl aminocyclopentitols with anticancer properties – Carbohydr Res. (2025)

  6. 🧬 Target-specific screening of anti-inflammatory phytosteroids using molecular docking – Steroids (2025)

  7. 🧪 Insect-derived antifungal peptides in Candida management – Int. J. Mol. Sci. (2025)

  8. 🧫 Azo-coumarin-Co(II)-galangin hybrids for multipotential activities – J. Biomol. Struct. Dyn. (2024)

  9. 🧒 Pediatric dermatology case analysis in Eastern India – Indian J. Paediatr. Dermatol. (2024)

  10. 🔬 Schiff/Mannich coumarin derivatives: Antibacterial and anti-biofilm evaluation – RSC Adv. (2024)

🧾 Conclusion:

Dr. Alaka Sahoo is highly suitable for the Research for Young Researcher Award. Her multi-disciplinary expertise, robust research record, and recognition through national awards highlight her as a promising early-career scientist. She combines academic rigor with innovation, and her work has meaningful implications for public health, especially in oral disease therapy, biofilm inhibition, and phytochemical-based drug development.

Xiaoyan Wang | Immunology Cellular Interactions | Best Paper Award

Published on by Cell Biologist

Ms. Xiaoyan Wang | Immunology Cellular Interactions | Best Paper Award

Ms. Xiaoyan Wang | Fudan University | China

Dr. Xiaoyan Wang is a dedicated cardiologist and postdoctoral fellow at Fudan University with a strong background in both clinical practice and cardiovascular research. With over a decade of academic training and medical experience, she has built expertise in ventricular remodeling, percutaneous coronary interventions, and immune responses in heart diseases. Under the mentorship of esteemed scholars such as Dr. Yunzeng Zou and Academician Yaling Han, she has published extensively in high-impact journals, reflecting her commitment to scientific advancement. Dr. Wang is currently a scholar in Harvard Medical School’s Global Clinical Scholars Research Training program and also serves as a section editor for the AME Clinical Trials Review. She actively contributes to academic communities, notably by organizing the “Excellent Academic Research Communication Club.” Her work bridges translational medicine and clinical application, aiming to improve cardiovascular patient outcomes through innovative, evidence-based approaches.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Outstanding Academic Credentials: Dr. Wang has earned her PhD from the prestigious Fudan University and is currently in the Harvard Medical School’s Global Clinical Scholars Research Training Program, signaling a top-tier academic and global research profile.

  2. Dual Research Strength in Basic and Clinical Sciences: She demonstrates an exceptional ability to bridge molecular mechanisms (e.g., immune pathways, cGAS-STING, miRNAs, circular RNAs) with clinical relevance (e.g., myocardial infarction prognosis, anemia impact in PCI), making her work highly translational.

  3. High-Impact Publications: First-author or co-first-author in peer-reviewed journals such as Signal Transduction and Targeted Therapy, Angiology, and Frontiers in Cardiovascular Medicine, with publications tackling cutting-edge cardiovascular topics.

  4. Collaborative and Interdisciplinary Focus: Contributions across institutions and disciplines—partnering with bioinformaticians, clinicians, and molecular scientists—demonstrate strong collaboration skills.

  5. Recognition & Editorial Role: Multiple awards (CPSF Fellowship, Super Postdoc at Fudan) and an editorial position at AME Clinical Trials Review show leadership and peer acknowledgment.

🛠️ Areas for Improvement:

  1. More First-Author Lead on Recent Papers: Although she holds strong co-first authorships and collaborative contributions, maintaining or increasing sole first-author outputs on impactful papers would further strengthen individual scholarly identity.

  2. Increased International Conference Visibility: While she has presented at JCS, continued or expanded visibility in global cardiovascular congresses (e.g., AHA, ESC, ACC) would enhance recognition.

  3. Grant Leadership: Future grant applications as a principal investigator (rather than team member) could affirm her leadership in project design and execution.

🎓 Education :

Dr. Xiaoyan Wang holds a Ph.D. from Fudan University’s Zhongshan Hospital (2016–2019), where she conducted fundamental research on ventricular remodeling under Dr. Yunzeng Zou’s mentorship, supported by prestigious national fellowships. She earned her Master’s degree from Dalian Medical University (2013–2016), focusing on clinical research in percutaneous coronary intervention, under Academician Yaling Han. Her academic foundation was laid with a Bachelor’s degree in Medicine from Fujian Medical University (2007–2012). Currently, she is advancing her research and clinical skills in the prestigious Global Clinical Scholars Research Training Program at Harvard Medical School (2024–2025), blending in-person and online modules. Her multi-tiered education reflects a deep integration of basic science, translational medicine, and clinical practice in cardiovascular health, equipping her to lead high-impact research and patient care initiatives.

💼 Experience:

Dr. Wang is currently a Postdoctoral Fellow at Fudan University (since 09/2023), working under Prof. Yunzeng Zou. She is also the organizer of the Excellent Academic Research Communication Club, promoting interdisciplinary dialogue. From 07/2022 to 07/2023, she served as a cardiologist at Shanghai Jiaotong University’s Ruijin Hospital, and from 2019 to 2022, as a resident in internal medicine at Zhongshan Hospital. In 2024, she began contributing as a section editor for AME Clinical Trials Review, enhancing the quality and visibility of clinical trial research. Her experience spans clinical cardiology, postdoctoral research, editorial responsibilities, and academic leadership. These roles have solidified her ability to translate scientific knowledge into medical practice, particularly in the cardiovascular field.

🏆 Awards & Honors:

Dr. Wang has received numerous accolades recognizing her academic excellence and research impact. In 2023, she was awarded both the Postdoctoral Fellowship Program of the China Postdoctoral Science Foundation (CPSF) and the prestigious Super Postdoctoral Fellowship of Fudan University, underscoring her leadership in postdoctoral research. Her communication and writing skills were acknowledged with the Third Prize in the 8th “Buchang Cup” Young Physician Essay Contest (2019). She also presented Late Breaking Cohort Studies at the Japanese Circulation Society (JCS) Annual Meeting 2019, reflecting international recognition of her scientific contributions. These honors reflect her potential as a rising leader in cardiovascular medicine and support her suitability for the Best Paper Award.

🔬 Research Focus :

Dr. Wang’s research focuses on cardiovascular disease mechanisms, particularly immune system regulation, ventricular remodeling, and the molecular basis of heart failure. Her Ph.D. and postdoctoral studies have addressed the cGAS-STING pathway, miRNA biomarkers, circular RNAs, and inflammation-related signaling in cardiovascular dysfunction. She has also explored clinical prognostic models, such as CHA2DS2-VASc scoring, and interventions including left atrial appendage occlusion and shock wave therapy for ischemic cardiomyopathy. Her dual interest in basic science and clinical outcomes allows her to design translational research that bridges laboratory findings and therapeutic advancements. With a strong publication record and ongoing involvement in global research training at Harvard Medical School, her work aims to inform precision medicine strategies in cardiology.

📚 Publication Titles Top Notes:

  1. 🧠 The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications

  2. 🔗 The connection of immune response and cGAS-STING pathway in cardiovascular disease

  3. 🐭 Left ventricular response in hypertrophy-to-failure transition: roles of Akt, β-arrestin-2, and CaMKII

  4. 💉 Circulating miRNAs in hypertension: diagnostic value and bioinformatics analysis

  5. 🧪 Galectin-3 inhibition improves endothelial progenitor function via autophagy suppression

  6. 🔄 Circular RNA in cardiovascular disease

📌 Conclusion:

Dr. Xiaoyan Wang is highly suitable for the Research for Best Paper Award. Her profile reflects a rare and valuable integration of basic cardiovascular science and clinical innovation, with high-impact, well-cited publications and ongoing international training. Her trajectory, marked by excellence, discipline, and collaborative leadership, meets and exceeds the criteria for this award.

Yimin Zhu | Immunology Cellular Interactions | Women Researcher Award

Published on by Cell Biologist

Prof. Yimin Zhu | Immunology Cellular Interactions | Women Researcher Award

Prof. Yimin Zhu , Suzhou Institute of Nanotechnology, Chinese Academy of Sciences , China

Prof. Yimin Zhu is a distinguished researcher in bioengineering, specializing in cancer therapies, biomaterials, and peptide screening platforms. With a background in both clinical medicine and biotechnology, she bridges the gap between medical applications and cutting-edge biotechnological innovations. Prof. Zhu completed her master’s in Clinical Medicine from Tianjin Medical University in 1996 and a Ph.D. in Biochemistry from the National University of Singapore in 2005. She has made significant contributions to cancer immunotherapy, drug delivery systems, and biomarker identification. Prof. Zhu’s work has led to over 30 first-author/co-corresponding publications in leading scientific journals, and she holds more than 20 patents. She currently holds a professorship at Suzhou Institute of Nano-Tech and Nano-Bionics, CAS, where her research continues to advance cancer treatments through novel molecular mechanisms and drug delivery platforms.

Publication Profile:

Scopus

Strengths for the Award:

  1. Interdisciplinary Expertise: Prof. Yimin Zhu has a unique blend of clinical medicine and advanced biotechnology expertise, making her well-suited to bridge the gap between medical practice and cutting-edge cancer research. Her background in both the clinical and research fields allows her to tackle cancer therapies from multiple angles.
  2. Impactful Research: Prof. Zhu’s research focuses on critical areas in cancer therapy, such as peptide-based immunotherapy, tumor mechanisms, drug delivery systems, and biomarker discovery. She has published over 30 high-impact papers in leading journals, showcasing her leadership in the field.
  3. Innovative Contributions: She has made substantial contributions to developing peptide-based bispecific CAR T cells and innovative drug delivery systems, with several patents granted. These innovations hold great promise for advancing cancer therapy and improving patient outcomes.
  4. Support and Funding: Prof. Zhu has successfully secured substantial research funding, including multiple grants from the National Natural Science Foundation of China, supporting her groundbreaking research in cancer immunotherapy and biomaterial development.

Areas for Improvement:

  1. Broader Outreach: Although Prof. Zhu has made impressive advancements in cancer research, expanding her work’s visibility to a broader audience in the medical and biotechnology communities, as well as among the general public, could increase the impact of her innovations.
  2. Collaboration and Mentorship: Further expanding interdisciplinary collaborations, particularly with social scientists or clinicians in oncology, could strengthen the practical application of her research and increase its translation into clinical practice. Additionally, mentoring young women in STEM could increase her contribution to fostering diversity in the field.
  3. Public Engagement: Enhancing communication efforts to present her research in a more accessible format for non-experts could be a significant avenue for impact, particularly in terms of attracting additional funding and public interest in her cancer-focused work.

Education:

Prof. Yimin Zhu’s educational journey reflects her interdisciplinary approach to bioengineering and medical science. She earned her Master’s degree in Clinical Medicine from Tianjin Medical University in 1996, where she initially focused on medical practice, gaining hands-on experience as a resident and consultant in Neurology. Her passion for scientific research led her to pursue a Ph.D. in Biochemistry from the National University of Singapore, completed in 2005. This transition to biochemistry allowed her to explore molecular biology, cancer research, and biotechnology. Prof. Zhu’s postdoctoral work at the University of California, Santa Barbara, in Chemical Engineering, further honed her expertise in nanotechnology, bioengineering, and therapeutic innovations. This broad educational foundation, combining clinical experience with cutting-edge research, has uniquely positioned her as a leader in cancer bioengineering and drug delivery systems.

Experience:

Prof. Yimin Zhu’s diverse experience spans both clinical medicine and high-impact research. Between 1996 and 2000, she worked as a resident and consultant doctor in Neurology, which provided a strong foundation in patient care and medical science. Transitioning to research, she served as a research fellow at the National University of Singapore from 2003 to 2005, focusing on biochemistry and cancer-related molecular mechanisms. Prof. Zhu further developed her expertise during her postdoctoral training in the Chemical Engineering Department at the University of California, Santa Barbara, where she explored the intersection of chemical engineering, nanotechnology, and therapeutic interventions. Since joining the Suzhou Institute of Nano-Tech and Nano-Bionics in 2008, she has been a professor, where she leads innovative research in peptide-based cancer therapies, immunotherapy, and drug delivery systems. Her extensive academic background and practical experience have earned her numerous patents and substantial research funding.

Research Focus:

Prof. Yimin Zhu’s research primarily focuses on bioengineering for cancer treatment, peptide screening platforms, and targeted drug delivery systems. Her work involves identifying molecular mechanisms behind tumor cell behavior and developing innovative methods for cancer diagnosis and therapy. She is dedicated to advancing cancer immunotherapy, particularly through the development of peptide-based bispecific CAR T cells targeting key proteins like EGFR and tumor stroma. Prof. Zhu’s research aims to enhance the efficacy of cancer treatments while minimizing side effects. Her studies also explore the development of smart delivery systems, such as extracellular vesicle-based nanodrugs, to improve the precision and effectiveness of drug delivery to tumor sites. Additionally, her work delves into the identification of cancer biomarkers, offering new ways to predict tumor metastasis and optimize treatment regimens. By combining molecular biology, nanotechnology, and biotechnology, Prof. Zhu’s research holds great promise for advancing personalized cancer care.

Publications Top Notes:

  • The peptide-based bispecific CAR T cells target EGFR and tumor stroma for effective cancer therapy 🧬
  • Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress 💉
  • Natural killer cells contribute to ‘hot’ tumor regression in the allergic inflammatory environment 🦠
  • Identification of cancer protein biomarker based on cell specific peptide and its potential role in predicting tumor metastasis 🔬
  • Extracellular Vesicle‐Based Nanodrug Delivery 💊
  • Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin 🧫
  • Dermatophagoides pteronyssinus allergen Der p 22: Cloning, expression, IgE-binding in asthmatic children, and immunogenicity 🌿
  • Reforming the Chimeric Antigen Receptor by Peptide Towards Optimized CAR T Cells With Enhanced Anti-Cancer Potency and Safety 🦠
  • Smart delivery of poly-peptide composite for effective cancer therapy 💡
  • The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells ⚙️

Conclusion:

Prof. Yimin Zhu’s research excellence, particularly in cancer therapy, peptide-based immunotherapy, and novel drug delivery systems, positions her as a highly deserving candidate for the Research for Women Researcher Award. Her interdisciplinary approach, groundbreaking innovations, and leadership in publishing high-impact scientific papers make her a trailblazer in the field of bioengineering. By addressing the areas for improvement, particularly in outreach and mentorship, Prof. Zhu could amplify her contributions even further, inspiring the next generation of women scientists and advancing the fight against cancer.

 

 

 

Bárbara Verçosa | Host-Pathogen Interactions | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Bárbara Verçosa | Host-Pathogen Interactions | Best Researcher Award

Prof. Dr. Bárbara Verçosa , Faculdade de Saude Pitágoras Codó , Brazil

Bárbara Laurice Araújo Verçosa, a Brazilian researcher and veterinarian, specializes in veterinary pathology and the study of leishmaniasis. She holds a Doctorate in Biology (2015) from Universidade Federal de Minas Gerais, with a focus on renal response in canine visceral leishmaniasis. She is a committed educator and scientific researcher, contributing extensively to the fields of veterinary medicine and animal pathology. She has published numerous papers in international journals, participated in various academic and professional events, and is an active member of editorial boards. Her contributions to veterinary science, especially in the study of inflammatory responses and apoptosis in leishmaniasis, have earned her recognition both nationally and internationally.

Publication Profile:

Scopus

Strengths for the Award:

  1. Academic Qualifications and Research Focus:
    Dr. Verçosa has a strong academic background, with a Doctorate in Biology from the Universidade Federal de Minas Gerais (UFMG) and a Master’s degree in Pathological Anatomy and Clinical Pathology from the same institution. Her research focuses on canine visceral leishmaniasis, which is highly relevant and impactful in veterinary medicine. Her expertise in apoptosis, inflammation, fibrosis, and renal pathology related to infectious diseases shows a high level of specialization and contribution to the field.
  2. Research Publications:
    Dr. Verçosa has an impressive publication record with 23 articles in reputable scientific journals, including high-impact journals such as Microbial Pathogenesis, Molecular Immunology, and Veterinary Parasitology. Additionally, she has authored books and chapters and has presented her research at numerous conferences. The breadth and depth of her publications demonstrate her active contribution to advancing knowledge in veterinary medicine, particularly in parasitic diseases.
  3. Experience and Knowledge:
    With significant experience in pathology, veterinary medicine, and molecular diagnostics, she brings a holistic understanding of both the basic and applied aspects of her field. Her experience in teaching, mentoring graduate students, and serving as a scientific journal referee further exemplifies her leadership in the academic and research community.
  4. Awards and Recognition:
    Dr. Verçosa’s work has been recognized with multiple awards such as the Menção Honrosa at the Seminário de Iniciação Científica and the 1st Prize in Scientific Initiation from Fapepi. These awards highlight her early career achievements and ongoing recognition in her research contributions.
  5. International Recognition and Collaborations:
    Dr. Verçosa is an active contributor to international research, with collaborations and refereeing roles in journals such as the Journal of Pharmaceutical Research International and the Asian Journal of Advances in Research, which reflects her international recognition and commitment to global scientific dialogue.

Areas for Improvement:

  1. Increase Interdisciplinary Collaborations:
    While Dr. Verçosa’s expertise is mainly within the veterinary and biological sciences domain, exploring interdisciplinary research with fields like public health, epidemiology, and clinical veterinary practices could further broaden the impact of her work, especially considering the public health implications of diseases like Leishmaniasis.
  2. Expanding Research into Novel Treatment Approaches:
    Given the ongoing challenges in treating Leishmaniasis in animals, expanding her research to explore new treatment protocols or innovative therapies in collaboration with clinicians could be a valuable area of growth. Exploring how her findings in inflammatory response and fibrosis can lead to better therapeutic options could strengthen the clinical relevance of her work.
  3. Increased Public Engagement:
    While her publications are substantial in academic circles, increasing public engagement through outreach programs or community awareness initiatives about canine Leishmaniasis and other diseases she studies could enhance her contribution to society. This could help bridge the gap between research and practical applications for the broader population.

Education:

Bárbara Verçosa holds a Doctorate (2015) in Biology from Universidade Federal de Minas Gerais (UFMG), Brazil, where she focused on inflammatory responses and apoptosis in dogs infected with Leishmania. She completed her Master’s in Pathological Anatomy and Clinical Pathology at UFMG in 2010, investigating apoptosis in naturally infected dogs. She earned her Veterinary Medicine degree from Universidade Federal do Piauí (UFPI) in 2007, specializing in the inflammatory responses in canine leishmaniasis. Additionally, Verçosa has participated in postdoctoral research at Universidade de Brasília (UnB), focusing on health sciences, and has completed several continuing education courses in diagnostic imaging, molecular diagnostics, and animal pathology.

Experience:

Verçosa has extensive academic and professional experience in veterinary medicine and pathology. She served as a faculty member at Universidade Regional do Cariri (URCA) and currently teaches at Faculdade de Ciências da Saúde Pitágoras Codó. She has been involved in research, graduate supervision, and clinical training in veterinary anatomy and pathology. Her research focus includes canine leishmaniasis, inflammatory responses, and apoptotic processes in infected tissues. Her career also includes several trainee and research positions, particularly in animal pathology at UFPI, and clinical practice in large animal surgery. Verçosa’s international exposure includes teaching and research roles at UFMG, where she taught pathology to veterinary students. Her involvement in research and scientific publication spans many years, with a focus on advancing the understanding of animal diseases through detailed anatomical and molecular studies.

Awards and Honors:

Bárbara Verçosa has received multiple awards for her research and academic contributions. Notably, she received two Honorable Mentions in 2006 for her presentations at the XIV Seminário de Iniciação Científica at UFPI. She was also awarded the 1st Prize for Scientific Initiation by Fapepi, the Foundation for Research Support of the State of Piauí, in 2005. These recognitions highlight her early dedication to scientific research. Verçosa’s career has also been distinguished by her scholarships from CAPES and CNPq, which supported her doctoral and master’s research. Her research excellence has been further validated by her ongoing involvement in prestigious journals as a reviewer, alongside her role in various editorial boards. Her academic achievements reflect her significant contributions to the fields of veterinary science and animal pathology.

Research Focus:

Bárbara Verçosa’s research primarily focuses on veterinary pathology, particularly in the context of visceral leishmaniasis in dogs. Her studies explore the inflammatory response, apoptosis, and fibrosis in organs affected by this parasitic disease. She investigates the molecular and histomorphometric changes in canine renal tissues, with an emphasis on the interactions between immune responses and tissue damage. Verçosa’s work also covers the role of chemokines, cytokines, and apoptosis markers in understanding the disease’s pathogenesis. Her research extends into other areas of veterinary pathology, including the study of animal inflammatory diseases and zoonotic diseases. Through her studies, she aims to contribute to improving diagnostic, therapeutic, and preventive measures for animal health. Verçosa’s interdisciplinary approach combines molecular biology, histopathology, and clinical studies, positioning her as a leading expert in veterinary parasitology.

Publications Top Notes:

  1. Enhanced apoptotic index in hepatocytes, Kupffer cells, and inflammatory infiltrate showed positive correlation with hepatic lesion intensity, parasite load, and clinical status in naturally Leishmania-infected dogs. (MICROBIAL PATHOGENESIS) 📚🦠
  2. MCP-1/IL-12 ratio expressions correlated with adventitial collagen depositions in renal vessels and IL4/IFN-γ expression correlated with interstitial collagen depositions in the kidneys of dogs with canine leishmaniasis. (MOLECULAR IMMUNOLOGY) 🧬🦠
  3. Nucleolar organizer region proteins enhancement in nucleoplasm’s of renal tubular cells is an indication of kidney impairment in Leishmania-infected dogs. (VETERINARY PARASITOLOGY) 🦠🧪
  4. Enhanced apoptotic index, chemokines and inflammatory recruitment in renal tissues shows relationship with the clinical signs in Leishmania-infected dogs. (VETERINARY PARASITOLOGY) 🔬🐶
  5. The balance between IL-12/IL4 in renal tissue switches the inflammatory response arm and shows relationship with the clinical signs in Leishmania-infected dogs (Veterinary Immunology and Immunopathology, 2021).

Conclusion:

Dr. Bárbara Laurice Araújo Verçosa is a highly accomplished and well-regarded researcher in the field of veterinary medicine, particularly in pathology and infectious diseases. Her extensive research publications, awards, and international collaborations are a testament to her expertise and impact in the field. The areas identified for improvement are relatively minor and pertain to enhancing the breadth and public visibility of her work. Overall, her scientific contributions make her an excellent candidate for the Best Researcher Award.